scholarly journals Low Yield of Stress Imaging in a Population-Based Study of Asymptomatic Patients After Percutaneous Coronary Intervention

2014 ◽  
Vol 7 (3) ◽  
pp. 438-445 ◽  
Author(s):  
Tyler Peterson ◽  
J. Wells Askew ◽  
Malcolm Bell ◽  
Daniel Crusan ◽  
David Hodge ◽  
...  
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Coronary Intervention ◽  
Population Based ◽  
Stress Imaging ◽  
Population Based Study ◽  
Asymptomatic Patients ◽  
Percutaneous Coronary

scholarly journals EFFECTIVENESS OF TICAGRELOR COMPARED TO CLOPIDOGREL IN REDUCING THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY HEART DISEASE AFTER PERCUTANEOUS CORONARY INTERVENTION

2017 ◽  
Vol 9 (9) ◽  
pp. 178 ◽  
Author(s):  
Hendra Wana Nur’amin ◽  
Iwan Dwiprahasto ◽  
Erna Kristin
Keyword(s):  
Myocardial Infarction ◽  
Coronary Heart Disease ◽  
Percutaneous Coronary Intervention ◽  
Heart Disease ◽  
Cardiovascular Events ◽  
Coronary Intervention ◽  
Population Based ◽  
Major Adverse Cardiovascular Events ◽  
Repeat Revascularization ◽  
Percutaneous Coronary

Objective: Antiplatelet therapy is recommended in patients with coronary heart disease (CHD) who had the percutaneous coronary intervention (PCI) procedure to reduce major adverse cardiovascular events (MACE). There has been a lack of population-based studies that showed the superior effectiveness of ticagrelor over clopidogrel and similar studies have not been conducted in Indonesia yet. The aim of the study was to investigate the effectiveness of ticagrelor compared to clopidogrel in reducing the risk of MACE in patients with CHD after PCI.Methods: A retrospective cohort study with 1-year follow-up was conducted. 361 patients consisted of 111 patients with ticagrelor exposure and 250 patients with clopidogrel exposure. The primary outcome was MACE, defined as a composite of repeat revascularization, myocardial infarction, or all-cause death. The association between antiplatelet exposure and the MACE was analyzed with Cox proportional hazard regression, adjusted for sex, age, comorbid, PCI procedures and concomitant therapy.Results: MACE occurred in 22.7% of the subjects. Clopidogrel had a significantly higher risk of MACE compared with ticagrelor (28.8%, vs 9.0%, hazard ratio (HR): 1.96 (95% CI 1.01 to 3.81, p=0.047). There were no significant differences in risk of repeat revascularization (20.40% vs 5.40%, HR: 2.32, 95% CI 0.99 to 5.42, p = 0.05), myocardial infarction (11.60% vs 3.60%, HR: 2.08, 95% CI, 0.73 to 5.93, p = 0.17), and death (1.60% vs 1.80%, HR: 0.77, 95% CI, 0.14 to 4.25, p = 0.77).Conclusion: Clopidogrel had a higher risk of MACE compared to clopidogrel in patients with CHD after PCI, but there were no significant differences in the risk of repeat revascularization, myocardial infarction, and all-cause death. 

Abstract 317: Implications of the Ischemia Trial Results on Appropriateness of Percutaneous Coronary Intervention for Stable Coronary Artery Disease: Insights From the Ncdr Cathpci Registry

2020 ◽  
Vol 13 (Suppl_1) ◽  
Author(s):  
Ali O Malik ◽  
John Spertus ◽  
kevin kennedy ◽  
Paul S Chan
Keyword(s):  
Percutaneous Coronary Intervention ◽  
Health Status ◽  
Coronary Artery ◽  
Stable Coronary Artery Disease ◽  
Coronary Intervention ◽  
Potential Implication ◽  
Asymptomatic Patients ◽  
Percutaneous Coronary ◽  
Artery Disease ◽  
To Receive

Background: The recent ISCHEMIA trial found that percutaneous coronary intervention (PCI) did not reduce rates of cardiovascular events (death, myocardial infarction) in patients with stable ischemic heart disease (SIHD), regardless of ischemic burden, but improved patients’ health status, if they had angina. These findings have significant implications for appropriate use criteria (AUC) for PCI and suggest that PCI in asymptomatic patients may be classified as rarely appropriate given the lack of cardiovascular event or health status benefit. Methods: Patients with SIHD, who were enrolled in the NCDR Cath-PCI registry v5, from April 1 st , 2018 to June 30 th , 2019 were included in this study. To examine the potential implication of the ISCHEMIA trial on AUC, we modified the AUC definition to reclassify PCIs in asymptomatic patients with SIHD (without left main coronary artery involvement) as rarely appropriate. We then compared the current and modified AUCs. Results: Our final analytical cohort included 324,715 patients (mean age 67.9 years, 11.3% non-Caucasian, 30.4% females). At baseline, comorbidities were common with 42.9% having diabetes, 56.8% being current or recent smokers and 16.0% having chronic lung disease. Based on the current AUC definition, 113,110 (34.8%) PCIs were classified as appropriate, 79,859 (24.6%) as maybe appropriate, 6,660(2.1%) as rarely appropriate, and 125,086 (38.5%) could not be classified. Recategorizing the AUCs based on ISCHEMIA, 51,502 (15.9%) PCIs were classified as rarely appropriate; with 22,753 being reclassified from maybe appropriate and 22,089 asymptomatic patients being reclassified from unclassifiable to rarely appropriate (Figure). Conclusion: One in five patients with SIHD who undergo PCI are asymptomatic and might not be considered rarely appropriate under current AUC. The ISCHEMIA trial may have large implications on the number and proportion of patients with SIHD considered to receive little to no benefit from elective PCI.

Sign in / Sign up

Export Citation Format

Share Document